Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
Nabi H, Georgiadis S, Loft AG, Hendricks O, Jensen DV, Andersen M, Chrysidis S, Colic A, Danebod K, Hussein MR, Kalisz MH, Kristensen S, Lomborg N, Manilo N, Munk HL, Pedersen JK, Raun JL, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Nabi H, et al. Ann Rheum Dis. 2021 Nov;80(11):1400-1409. doi: 10.1136/annrheumdis-2021-219951. Epub 2021 Apr 29. Ann Rheum Dis. 2021. PMID: 33926921
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H, Hendricks O, Jensen DV, Loft AG, Pedersen JK, Just SA, Danebod K, Munk HL, Kristensen S, Manilo N, Colic A, Linauskas A, Thygesen PH, Christensen LB, Kalisz MH, Lomborg N, Chrysidis S, Raun JL, Andersen M, Mehnert F, Krogh NS, Hetland ML, Glintborg B. Nabi H, et al. RMD Open. 2022 Nov;8(2):e002560. doi: 10.1136/rmdopen-2022-002560. RMD Open. 2022. PMID: 36418087 Free PMC article.
Implementing Multifactorial Risk Assessment with Polygenic Risk Scores for Personalized Breast Cancer Screening in the Population Setting: Challenges and Opportunities.
Walker MJ, Blackmore KM, Chang A, Lambert-Côté L, Turgeon A, Antoniou AC, Bell KA, Broeders MJM, Brooks JD, Carver T, Chiquette J, Després P, Easton DF, Eisen A, Eloy L, Evans DG, Fienberg S, Joly Y, Kim RH, Kim SJ, Knoppers BM, Lofters AK, Nabi H, Paquette JS, Pashayan N, Sheppard AJ, Stockley TL, Dorval M, Simard J, Chiarelli AM. Walker MJ, et al. Among authors: nabi h. Cancers (Basel). 2024 May 31;16(11):2116. doi: 10.3390/cancers16112116. Cancers (Basel). 2024. PMID: 38893236
Rediscovering citrate as a biomarker for prostate cancer.
Galey L, Olanrewaju A, Nabi H, Paquette JS, Pouliot F, Audet-Walsh É. Galey L, et al. Among authors: nabi h. Nat Rev Urol. 2024 May 29. doi: 10.1038/s41585-024-00899-3. Online ahead of print. Nat Rev Urol. 2024. PMID: 38811764 No abstract available.
Mapping inter-professional collaboration in oncogenetics: Results from a scoping review.
Espinoza-Moya ME, Guertin JR, Floret A, Dorval M, Lapointe J, Chiquette J, Bouchard K, Nabi H, Laberge M. Espinoza-Moya ME, et al. Among authors: nabi h. Crit Rev Oncol Hematol. 2024 Jul;199:104364. doi: 10.1016/j.critrevonc.2024.104364. Epub 2024 May 9. Crit Rev Oncol Hematol. 2024. PMID: 38729319 Free article. Review.
247 results